Chronic myeloid leukemia (CML) cells express the active BCR-ABL1 protein, which has been targeted by imatinib in CML therapy, but resistance to this drug is an emerging problem. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.